Antag Therapeutics Raises €80 Million in Series A to Drive Obesity and Cardiometabolic Therapies

Antag Therapeutics, a clinical-stage biopharmaceutical company specializing in therapies for obesity and cardiometabolic diseases, has successfully secured €80 million in a Series A financing round. The round was led by Versant Ventures, a distinguished healthcare venture capital firm, with participation from Dawn Biopharma, SR One, and Pictet Alternative Advisors. The multi-national legal team from Goodwin advised the syndicate of investors on the deal. Other significant contributors to the financing round included Novo Holdings, Longview Ventures, and the Export and Investment Fund of Denmark. The proceeds from this funding will enable Antag Therapeutics to advance its clinical development of AT-7687, a novel weekly subcutaneous antagonist, and further the expansion of their therapy pipeline. Versant Ventures, recognized for fostering innovative biotech companies, holds a diverse, global portfolio with a potent mix of investment and R&D capabilities. Concurrently, Dawn operates under KKR’s platform, focusing on transformative medical developments. The financing is anticipated to escalate Antag’s efforts in addressing unmet medical needs through GIP receptor antagonism.